Clene Inc is a biotechnology company focused on developing innovative therapeutics to address neurodegenerative diseases

The company utilizes its proprietary nanotechnology platform to create novel drug candidates that target various neurological conditions, aiming to improve patient outcomes and enhance quality of life. Clene's research and development efforts are centered around harnessing the unique properties of nanomaterials to facilitate the delivery and effectiveness of its treatments, which hold promise for a range of disorders, including multiple sclerosis and amyotrophic lateral sclerosis. Through cutting-edge science and a commitment to advancing neurotherapeutics, Clene seeks to make a meaningful impact on the treatment landscape for patients suffering from debilitating neurological illnesses.